The grounded valuation is based on a normalized EV/EBITDA multiple of approximately 11x on projected 2026 EBITDA of ~$375M, in line with comparable mission-critical infrastructure service providers, with a moderate discount for regulatory/litigation risk. Share count is based on the most recent rep…
SHC Q2 2026: Sterigenics Growth Lifts Guidance as X-Ray, Outsourcing Tailwinds Build
Sotera Health (SHC) delivered a guidance raise on the back of robust Sterigenics volume growth and margin expansion, with new X-ray capacity and a major insourcing-to-outsourcing customer shift set to drive second-half acceleration. The company’s disciplined capital deployment and cross-business integration efforts signal a strategic pivot toward higher-value, full-solution offerings. Investors should watch for sustained pricing power and the operational ramp of new modalities as key levers for outperformance into 2027.
Summary
- Sterigenics Outperformance: Volume growth and new outsourcing wins underpin confidence in second-half acceleration.
- Capital Allocation Reset: Leverage target achieved, with CapEx peaking as facility upgrades and X-ray expansion near completion.
- Strategic Integration: Cross-unit “One Sotera” initiatives and full-modality offerings are positioned to deepen customer stickiness.
Business Overview
Sotera Health (SHC) is a global provider of mission-critical sterilization and lab testing services for healthcare and life sciences manufacturers. The company generates revenue through three primary segments: Sterigenics, sterilization services across EO (ethylene oxide), gamma, and X-ray modalities; Nordion, supplier of Cobalt-60 for gamma sterilization; and Nelson Labs, provider of microbiological and analytical testing. SHC’s business model is anchored in long-term customer contracts and recurring service demand, with a focus on quality, regulatory compliance, and operational reliability.
Performance Analysis
SHC posted a sequential margin improvement, driven by Sterigenics’ 7% constant currency growth and Nelson Labs’ 5.4% constant currency revenue gain. Segment income margin improved 438 basis points quarter-over-quarter, returning to the company’s long-term low to mid-30% range, despite higher year-over-year costs. The company achieved positive operating cash flow and reduced net leverage to its target range, supporting a proactive capital allocation stance.
Nelson Labs benefited from both transient project wins and ongoing customer demand, with management noting a mix of one-off and recurring business contributing to the quarter’s outperformance. Sterigenics saw stable demand across its broad customer base, with particular momentum from a large customer shifting from insourcing to outsourcing sterilization, and the ramp-up of new X-ray capacity. Nordion’s revenue timing shifted more into Q2, but full-year growth remains on track.
- Margin Expansion: Sequential segment margin improvement reflects operating leverage and project-driven revenue mix, offsetting inflationary headwinds.
- CapEx Surge: Capital expenditures rose to $46 million in Q2, funding capacity expansion and facility upgrades, with a full-year peak expected before a step-down in 2027.
- Pricing Discipline: Company-wide pricing gains in the 3% to 4% range are supported by value-based commercial strategy and successful pass-through of EO facility enhancements.
Overall, SHC’s results demonstrate operational resilience, pricing power, and a platform for second-half acceleration as new capacity and customer wins ramp.
Executive Commentary
"These results reflect the essential role we play in supporting healthcare around the world, the strong partnerships we have built with our customers, the resilience of our business, and the commitment of our teams. I'm excited about the opportunities ahead and confident in our ability to execute on our priorities and to create long-term value for our stakeholders."
Alton [LastName], Chief Executive Officer
"Our net leverage ratio further improved to three times for the second quarter, marking an important milestone as we reached our long-term target leverage range of two to three times and our liquidity remains strong. As Alton noted, we are increasing our 2026 outlook for both revenue and adjusted EBITDA constant currency growth."
Jon [LastName], Chief Financial Officer
Strategic Positioning
1. Sterigenics: Volume and Outsourcing Tailwinds
Sterigenics, SHC’s largest segment, is leveraging both organic volume growth and a significant customer outsourcing shift to drive above-peer performance. The business benefits from a diverse customer base, with over 2,000 accounts providing stability and resilience. Management highlighted a favorable facility shutdown schedule and the onboarding of a large customer transitioning from insourced to outsourced EO sterilization, which will materially boost second-half results.
2. X-Ray and Modality Diversification
SHC’s investment in new X-ray sterilization capacity is a strategic response to customer demand for full-modality solutions. The new facility is on track, with revenue contribution beginning in Q3 and a strong validation pipeline. While gamma (Cobalt-60) remains core, X-ray is positioned as a complementary offering, with flexible cost structure and no material margin dilution expected. The company’s approach ensures it can meet evolving regulatory and customer requirements across modalities.
3. Nelson Labs: Integrated Growth Engine
Nelson Labs delivered strong sequential margin improvement and is increasingly integrated with Sterigenics in cross-unit solutions. Management cited both transient and recurring project wins, with the business model benefitting from validation testing and clean room expansion. The “One Sotera” initiative aims to drive deeper customer relationships and higher share of wallet by combining lab and sterilization capabilities.
4. Capital Allocation and Balance Sheet Strength
SHC reached its long-term leverage target and maintains robust liquidity, enabling continued investment in organic and inorganic growth. CapEx is peaking in 2026 to fund growth projects and facility enhancements, with a step-down expected in 2027. Management is actively reviewing capital allocation priorities, with a near-term focus on internal investment and targeted M&A, particularly in sterilization and lab services.
5. Pricing Power and Commercial Execution
Disciplined pricing remains a core lever, with management emphasizing value-based pricing for EO enhancements and consistent 3% to 4% company-wide price realization. The commercial team’s ability to secure price increases without notable customer pushback or competitive erosion is a key differentiator in a cost-inflationary environment.
Key Considerations
SHC’s Q2 results reflect a pivotal moment, with operational momentum and strategic investments converging to set the stage for accelerated growth and margin expansion in the second half and beyond.
Key Considerations:
- Outsourcing Shift: A major customer’s move from insourcing to outsourcing EO sterilization is a structural win that will boost volume and revenue mix.
- X-Ray Ramp and Modality Flexibility: The new X-ray facility expands SHC’s addressable market and meets rising regulatory and customer demand for diversified sterilization options.
- Integrated Solutions: “One Sotera” cross-business initiatives are designed to drive higher customer retention, expanded share of wallet, and differentiated service offerings.
- CapEx Inflection: 2026 marks a peak in capital expenditures as growth projects and facility enhancements near completion, with a step-down expected in 2027 and free cash flow commitments on track.
- Pricing and Margin Discipline: Sustained pricing power and margin management are critical as inflation persists, with management confident in maintaining target ranges.
Risks
Key risks include ongoing inflationary pressure on labor and materials, although management characterizes these as standard and manageable. Regulatory and litigation risks persist, particularly in EO sterilization, with ongoing legal proceedings in Georgia and California. Capacity constraints in specific geographies or modalities (notably large-chamber EO in the U.S.) could limit growth if demand outpaces expansion. Competitive dynamics remain intense, but no material shifts were noted this quarter. Execution risk around new facility ramp and cross-unit integration also warrants monitoring.
Forward Outlook
For Q3 2026, SHC guided to:
- Sterigenics: Mid to high single-digit constant currency revenue growth, with sequential acceleration expected.
- Nelson Labs: Low single-digit constant currency revenue growth, maintaining margin in the low to mid-30% range.
For full-year 2026, management raised guidance:
- Total company revenue growth of 5.25% to 6.75% constant currency.
- Adjusted EBITDA growth of 5.75% to 7.25% constant currency.
- Adjusted EPS range increased to $0.95 to $1.01 per diluted share.
- CapEx of $200 million to $225 million, with 2027 expected to step down.
Management cited strong volume visibility, the ramp of new X-ray capacity, and a major customer outsourcing win as drivers of improved confidence.
- Stable demand and backlog support the raised outlook.
- Pricing and operational discipline are expected to offset cost headwinds.
Takeaways
SHC is executing on a multi-pronged growth strategy, with volume, pricing, and integration levers all contributing to an improved outlook. The company’s ability to monetize new capacity and deepen customer relationships through integrated offerings positions it well for sustained value creation.
- Sterigenics and X-ray Expansion: Volume growth and new capacity are set to drive a second-half inflection, with a structural boost from customer outsourcing.
- Operational and Financial Discipline: Margin expansion, leverage reduction, and CapEx control signal robust execution and balance sheet strength.
- 2027 Watchpoints: Investors should monitor the operational ramp of new facilities, pricing sustainability, and the realization of cross-business synergies as key drivers of future upside.
Conclusion
Sotera Health’s Q2 2026 results mark a turning point, with robust Sterigenics growth, disciplined capital management, and strategic integration efforts converging to support a raised outlook. The company’s focus on full-modality solutions and operational excellence positions it for durable growth and margin resilience into 2027.
Industry Read-Through
SHC’s strong Sterigenics performance and X-ray ramp signal continued demand for outsourced, multi-modality sterilization in healthcare and life sciences supply chains. The shift of major customers from insourcing to outsourcing reflects a broader trend toward specialized providers able to ensure regulatory compliance and operational reliability. Margin expansion in the face of inflation demonstrates pricing power for critical infrastructure providers. Competitors and adjacent service providers should note the value of cross-unit integration and the importance of diversified modality offerings as regulatory and customer preferences evolve. Capital allocation discipline and operational leverage will differentiate winners as the sector navigates ongoing cost and compliance pressures.